Actionable Opportunities for Molecularly Classified Endometrial Cancers

This activity is part of a series


Richard T. Penson, MD, MRCP
Physician, Mass General Brigham
Associate Professor, Harvard Medical School
Institutional Review Board (IRB) Chair, Dana Farber Harvard Cancer Center
Boston, MA
Richard T. Penson, MD, MRCP

Richard T. Penson, MD, MRCP, is a Medical Oncologist at Massachusetts General Hospital, and Associate Professor of Medicine at Harvard Medical School. A key opinion leader, Dr. Penson was a longstanding member of the Gynecologic Oncology Group Ovarian and Quality of Life Committees and now serves on the Foundation’s Investigator Council. He is the national Principal Investigator (PI) of the olaparib registration trial (SOLO-2) and the international PI of SOLO3, and the OVAL trial. He has taught on Harvard’s Practice of Medicine Course, the Bigelow General Medical Service at Massachusetts General Hospital, and is one of the Chairs of the Institutional Review Board of Dana-Farber Harvard Cancer Center.

Matthew A. Powell, MD
Professor & Chief
Division of Gynecologic Oncology
Washington University School of Medicine
Saint Louis, MO

Statement of Need

Multiple clinical practice guidelines for the treatment of endometrial cancer (EC) recommend consideration of molecular testing, particularly for high-grade tumors. Yet despite its prognostic value, molecular classification is not always a part of standard risk assessment in EC. Clinical uptake has been highly variable, particularly in limited-resource areas, even though recent data shows molecular classification has value in therapeutic decision-making and is prognostic for treatment response in EC. Lack of clinical uptake has resulted in overtreatment of some EC patients and undertreatment of others.

During this informational podcast, leading national endometrial cancer experts, Drs. Richard Penson and Matthew Powell, will discuss molecular classification of EC and the clinical data supporting its value in EC care.

Learning Objectives

At the conclusion of this activity, learners will be able to better:

  • Identify the therapeutic implications of molecular classification on immuno-oncology therapeutic approaches for advanced or recurrent EC

Financial Support

Supported by a joint educational grant from AstraZeneca Pharmaceuticals and Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.

Target Audience

Primary Audiences: Medical oncologists, gynecologic oncologists, physician assistants (PAs), nurses, nurse practitioners (NPs), and pharmacists working in oncology settings
Secondary Audiences: Gynecologists and primary care physicians (PCPs)

Credit Information

Jointly Accredited Provider

In support of improving patient care, CME Outfitters, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Interprofessional (IPCE) 0.5

This activity was planned by and for the healthcare team, and learners will receive 0.50 Interprofessional Continuing Education Credit for learning and change.

Physicians (ACCME) 0.5

CME Outfitters, LLC, designates this Enduring Material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses (ANCC) 0.5

This activity is designated for 0.50 contact hours.

Pharmacists (ACPE) 0.5

This application-based activity is approved for 0.50 contact hours ( 0.05 CEUs) of continuing pharmacy credit ( JA0007185-0000-23-143-H01-P ).

PAs (AAPA) 0.5

CME Outfitters, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.50 AAPA Category 1 CME credits. Approval is valid until 11/30/2024. PAs should only claim credit commensurate with the extent of their participation.

MIPS Improvement Activity

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Royal College MOC

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Disclosure Declaration

Dr. Penson reports the following financial relationships:

Advisory Board: Aadi Bioscience; AstraZeneca; GSK; ImmunoGen, Inc.; Merck & Co., Inc.; Mersana Therapeutics; Novacure; Roche; Sutro Biopharma, Inc.; and Vascular Biogenics
Consultant: Serves on DSMBs for AstraZeneca; EQRx; and Roche
Research Support: Intuitional research funding (as PI) for Array BioPharma Inc.; AstraZeneca; Eisai Inc.; Genentech, Inc.; and Vascular Biogenics
Other financial or material support: Royalties: BMJ Publishing Group Ltd; Elsevier; UpToDate, Inc.; Wolters Kluwer Health and Wiley-Blackwell. Payment for educational events: Research to Practice; ExpertConnect; and ReachMD

Dr. Powell reports the following financial relationships:

Consultant: AstraZeneca; Clovis Oncology; Eisai Inc.; GSK; Jazz Pharmaceuticals, Inc.; Merck & Co., Inc.; Roche; and Seagen Inc.
Grants: National Cancer Institute (NCI) and Department of Defense (DoD)
Research Support: GSK

The following individuals have no financial relationships to disclose: 

Marlon “Tony” Graham, MD (Peer Reviewer)
Albert Eubanks, RN (Peer Reviewer)
Thomas Mitchell (Planning Committee)
David Modrak, PhD (Planning Committee)
Susan H. Yarbrough, CHCP (Planning Committee)
Sandra Caballero, PharmD (Planning Committee)
Sharon Tordoff (Planning Committee)

Obtaining Credit

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit our Privacy & Confidentiality page.

Questions about this activity?

Call us at 877.CME.PROS (877.263.7767).


Actionable Opportunities for Molecularly Classified Endometrial Cancers
Event Date: 11/30/2023 at 5:00 am EST